Accelerating Biomedical Innovation Act This bill requires the Department of Health and Human Services to establish, through a consortium of institutions of higher education, a center to accelerate the development of advanced medical countermeasures. (These are certain medical products that may be used to diagnose, prevent, or treat conditions associated with chemical, biological, radiological, or nuclear threats or emerging infectious diseases during public health emergencies.) The center must work on drugs or devices that are selected by the Biomedical Advanced Research and Development Agency (BARDA). A drug or device is eligible for selection if it incorporates a novel technology (or uses an existing technology in a novel way) in a manner that substantially (1) furthers the development of a drug or device of interest, (2) fulfills an unmet need, or (3) develops the manufacturing process for a drug or device. The bill also requires BARDA to coordinate with international partners to encourage global efforts to advance medical countermeasures.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health
Accelerating Biomedical Innovation Act
USA118th CongressS-1441| Senate
| Updated: 5/4/2023
Accelerating Biomedical Innovation Act This bill requires the Department of Health and Human Services to establish, through a consortium of institutions of higher education, a center to accelerate the development of advanced medical countermeasures. (These are certain medical products that may be used to diagnose, prevent, or treat conditions associated with chemical, biological, radiological, or nuclear threats or emerging infectious diseases during public health emergencies.) The center must work on drugs or devices that are selected by the Biomedical Advanced Research and Development Agency (BARDA). A drug or device is eligible for selection if it incorporates a novel technology (or uses an existing technology in a novel way) in a manner that substantially (1) furthers the development of a drug or device of interest, (2) fulfills an unmet need, or (3) develops the manufacturing process for a drug or device. The bill also requires BARDA to coordinate with international partners to encourage global efforts to advance medical countermeasures.